ERIN PERDUE: Open Payments
NPI 1275949455 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$996 in 41 payments from 16 companies in 2025. Trend: 2023 $1,622 · 2024 $1,767 · 2025 $996
Food & beverage: $943Education: $53
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $164 |
| Regeneron Healthcare Solutions, Inc. | 6 | $144 |
| GENZYME CORPORATION | 4 | $116 |
| Verona Pharma, Inc. | 5 | $107 |
| Amgen Inc. | 3 | $74 |
| Actelion Pharmaceuticals US, Inc. | 3 | $70 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| SANOFI-AVENTIS U.S. LLC | 1 | $53 |
| United Therapeutics Corporation | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
Products named: DUPIXENT, NUCALA, Ohtuvayre, TEZSPIRE, Tyvaso, OPSUMIT, FASENRA, GLASSIA.
Industry payments across MD — which companies pay providers there.
